このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Applied DNA Sciences マネジメント

マネジメント基準チェック /44

Applied DNA Sciences'の CEO はJames Haywardで、 Apr2006年に任命され、の在任期間は 18.17年です。の年間総報酬は$ 468.00Kで、 96.2%給与と3.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.066%を直接所有しており、その価値は$ 3.09K 。経営陣と取締役会の平均在任期間はそれぞれ9.3年と8.3年です。

主要情報

James Hayward

最高経営責任者

US$468.0k

報酬総額

CEO給与比率	96.2%
CEO在任期間	18.2yrs
CEOの所有権	0.07%
経営陣の平均在職期間	9.3yrs
取締役会の平均在任期間	8.3yrs

経営陣の近況

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Aug 02

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Jul 25

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

May 18

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?

Sep 17

CEO報酬分析

Applied DNA Sciences の収益と比較して、James Hayward の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$7m
Sep 30 2023	US$468k	US$450k	-US$10m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	US$2m	US$450k	-US$8m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	US$1m	US$400k	-US$14m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	US$451k	US$133k	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	US$375k	US$233k	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$481k	US$250k	-US$12m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	n/a	n/a	-US$12m
Sep 30 2017	US$546k	US$282k	-US$13m

報酬と市場: Jamesの総報酬 ($USD 468.00K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Jamesの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

James Hayward (70 yo)

18.2yrs

在職期間

US$468,000

報酬

Dr. James A. Hayward, Ph D., Sc D., has been Chief Executive Officer and Chairman of Applied DNA Sciences, Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and since June 12, 2007...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
James Hayward	Chairman	18.2yrs	US$468.00k	0.066% $ 2.7k
Beth Jantzen	Chief Financial Officer	9.3yrs	US$501.00k	0.020% $ 837.3
Judith Murrah	COO, Chief Information Officer & Secretary	11yrs	US$542.75k	0.023% $ 954.6
Clay Shorrock	Chief Legal Officer & Executive Director of Business Development	3.2yrs	US$501.00k	0.027% $ 1.1k
Sanjay Hurry	Executive Director of Investor Relations & Corporate Communications	3.9yrs	データなし	データなし

9.3yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: APDNの経営陣は経験豊富で経験豊富です（平均在職期間は9.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
James Hayward	Chairman	18.8yrs	US$468.00k	0.066% $ 2.7k
Robert Catell	Chairman of Strategic Advisory Board & Independent Director	8.3yrs	US$152.50k	0.00095% $ 39.6
Yacov Shamash	Independent Director	18.3yrs	US$162.50k	0.00077% $ 32.1
Raymond Kelly	Member of Strategic Advisory Board	7.4yrs	データなし	データなし
Joseph Ceccoli	Independent Director	9.5yrs	US$155.00k	0.00027% $ 11.3
Sanford Simon	Independent Director	18.3yrs	US$151.25k	0.000040% $ 1.7
Mehmood Khan	Member of Strategic Advisory Board	7.7yrs	データなし	データなし
Gunther Faber	Member of Strategic Advisory Board	8.3yrs	データなし	データなし
Elizabeth M. Shaheen	Independent Director	7yrs	US$153.75k	0.00038% $ 15.9
Stephen Birkhold	Member of Strategic Advisory Board	5.4yrs	データなし	データなし

8.3yrs

平均在職期間

73yo

平均年齢

経験豊富なボード: APDNの取締役会は経験豊富であると考えられます ( 8.3年の平均在任期間)。

Applied DNA Sciences マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Insufficient new directors

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Recent updates

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Price target decreased to US$5.00

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Consensus revenue estimates increase by 20%

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Price target decreased to US$12.00

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

マネジメント基準チェック /44